Contrasting Sientra (SIEN) and The Competition
Sientra (NASDAQ: SIEN) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its competitors? We will compare Sientra to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.
This table compares Sientra and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Sientra has a beta of -1.43, suggesting that its share price is 243% less volatile than the S&P 500. Comparatively, Sientra’s competitors have a beta of 1.06, suggesting that their average share price is 6% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Sientra and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sientra presently has a consensus price target of $13.75, suggesting a potential downside of 9.30%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 8.24%. Given Sientra’s competitors higher possible upside, analysts clearly believe Sientra has less favorable growth aspects than its competitors.
Institutional & Insider Ownership
77.6% of Sientra shares are owned by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 28.1% of Sientra shares are owned by company insiders. Comparatively, 11.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Sientra and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Sientra||$28.68 million||-$35.42 million||-5.70|
|Sientra Competitors||$827.23 million||$159.50 million||36.89|
Sientra’s competitors have higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Sientra competitors beat Sientra on 8 of the 12 factors compared.
Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.